TELA Bio Grants 3,600 Restricted Stock Units to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: Globenewswire
- Employee Incentive Program: TELA Bio has granted 3,600 restricted stock units to three newly hired employees, aiming to attract talent through an appealing compensation package, thereby enhancing the company's competitiveness in the medical technology sector.
- Grant Details: The grant date for these restricted stock units is December 9, 2025, and they were issued under the Nasdaq Rule 5635(c)(4) inducement grant exception, indicating the company's emphasis on incentive measures during recruitment.
- Vesting Arrangement: The granted stock units will vest in equal annual installments over four years, ensuring stability among new hires during their tenure, which will help improve overall team execution and business continuity.
- Company Vision: TELA Bio focuses on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, further solidifying its position in the medical technology market.
Analyst Views on TELA
Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is 3.31 USD with a low forecast of 1.25 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.980
Low
1.25
Averages
3.31
High
5.00
Current: 0.980
Low
1.25
Averages
3.31
High
5.00
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
